Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc.verified

ACRS

Price:

$4.07

Market Cap:

$290.72M

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moder...[Read more]

Industry

Medical - Diagnostics & Research

IPO Date

2015-10-06

Stock Exchange

NASDAQ

Ticker

ACRS

The Enterprise Value as of November 2024 (TTM) for Aclaris Therapeutics, Inc. (ACRS) is 243.07M

According to Aclaris Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 243.07M. This represents a change of 415.67% compared to the average of 47.14M of the last 4 quarters.

Aclaris Therapeutics, Inc. (ACRS) Historical Enterprise Value (quarterly & annually)

How has ACRS Enterprise Value performed in the past?

The mean historical Enterprise Value of Aclaris Therapeutics, Inc. over the last ten years is 360.29M. The current 243.07M Enterprise Value has changed 6.65% with respect to the historical average. Over the past ten years (40 quarters), ACRS's Enterprise Value was at its highest in in the March 2021 quarter at 1.24B. The Enterprise Value was at its lowest in in the March 2020 quarter at 488.17K.

Quarterly (TTM)
Annual

Average

360.29M

Median

224.53M

Minimum

33.85M

Maximum

982.53M

Aclaris Therapeutics, Inc. (ACRS) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Aclaris Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 442.86%

Maximum Annual Enterprise Value = 982.53M

Minimum Annual Increase = -96.56%

Minimum Annual Enterprise Value = 33.85M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
202333.85M-96.56%
2022982.53M23.09%
2021798.21M243.53%
2020232.35M442.86%
201942.80M-80.25%
2018216.70M-55.25%
2017484.29M-12.11%
2016551.05M256.27%
2015154.67M45.30%
2014106.45M-1.09%

Aclaris Therapeutics, Inc. (ACRS) Average Enterprise Value

How has ACRS Enterprise Value performed in the past?

The current Enterprise Value of Aclaris Therapeutics, Inc. (ACRS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

604.86M

5-year avg

417.95M

10-year avg

360.29M

Aclaris Therapeutics, Inc. (ACRS) Enterprise Value vs. Peers

How is ACRS’s Enterprise Value compared to its peers?

Aclaris Therapeutics, Inc.’s Enterprise Value is less than Neogen Corporation (3.84B), less than Qiagen N.V. (10.58B), less than Olink Holding AB (publ) (3.16B), less than Syneos Health, Inc. (7.24B), less than Sotera Health Company (5.78B), less than RadNet, Inc. (7.04B), less than Myriad Genetics, Inc. (1.52B), greater than Genetron Holdings Limited (0), greater than Biodesix, Inc. (240.02M), less than Castle Biosciences, Inc. (779.84M), greater than Prenetics Global Limited (29.28M), less than IQVIA Holdings Inc. (48.58B), less than Medpace Holdings, Inc. (10.06B), less than ICON Public Limited Company (20.24B),

Build a custom stock screener for Aclaris Therapeutics, Inc. (ACRS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aclaris Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Aclaris Therapeutics, Inc. (ACRS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Aclaris Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Aclaris Therapeutics, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Aclaris Therapeutics, Inc. (ACRS)?

What is the 3-year average Enterprise Value for Aclaris Therapeutics, Inc. (ACRS)?

What is the 5-year average Enterprise Value for Aclaris Therapeutics, Inc. (ACRS)?

How does the current Enterprise Value for Aclaris Therapeutics, Inc. (ACRS) compare to its historical average?